MYRIAD GENETIC LABORATORIES INC

Myriad Genetic Laboratories Inc. specializes in advanced molecular diagnostics and genomic testing services, primarily delivering clinically validated genetic assays for cancer risk assessment and personalized medicine. Their core expertise lies in proprietary DNA-based testing platforms, including the PROLARIS assay for prostate cancer prognosis, which enables clinicians to stratify patient risk and guide treatment decisions with precision. The company provides high-complexity clinical laboratory services under CLIA and CAP standards, with deep proficiency in next-generation sequencing, bioinformatics analysis, and biomarker interpretation. Their technical differentiation stems from validated genomic panels designed for clinical adoption in oncology and inherited disease screening, ensuring reproducible, actionable results for patient care. The contractor maintains a consistent and longstanding relationship with the Department of Veterans Affairs, where they deliver targeted genetic testing services to support veteran healthcare decisions, particularly in prostate cancer management. They also serve the Department of Health and Human Services through comprehensive laboratory services that support public health initiatives and research programs, often involving genomic data generation and clinical validation workflows. These engagements reflect a pattern of trusted, recurring partnerships rooted in reliable, high-quality diagnostic delivery. Myriad Genetic Laboratories operates primarily under NAICS 621511 (Medical Laboratories), focusing on clinical genomic testing, and secondarily under 541380 (Testing Laboratories and Services), indicating their dual role as both a diagnostic provider and a technical service partner. Their market positioning centers on precision medicine in oncology, with a strong emphasis on evidence-based genetic diagnostics adopted in federal healthcare systems. As a privately held entity based in Salt Lake City, Utah, the company maintains a focused operational footprint centered on its clinical laboratory infrastructure. While no federal certifications are listed, their consistent performance under federal contracts demonstrates adherence to stringent regulatory and quality standards required for government-funded healthcare services.